IVIS Spectrum CT Imaging System in BSL-3 Containment

BSL-3 安全壳内的 IVIS Spectrum CT 成像系统

基本信息

项目摘要

DESCRIPTION (provided by applicant): This Shared Instrumentation Grant (PAR-12-017) requests funds to purchase an IVIS Spectrum CT in vivo imaging system for non-invasive, longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals through bioluminescent and fluorescent two- or three- dimensional imaging co-registered with small animal computed tomography (CT). Importantly the instrument will be housed within the Pre-Clinical Imaging Core inside the Regional Bio containment Laboratory (RBL) at the University of Pittsburgh offering three major benefits: 1) housing within a 27,000 square foot facility, purpose-built to provide laboratory suites and core facilities operating unde Biosafety Level (BSL)-3 and Animal Biosafety Level (ABSL)-3; 2) registration to handle numerous Select Agent viral and bacterial pathogens and toxins; 3) housing for a wide range of animal species in bio containment caging, from mice to non-human primates (NHPs); 4) association with the Center for Vaccine Research (CVR), whose well-funded faculty have research interests and expertise related to the study of these highly pathogenic organisms and utilize the RBL BSL-3/ABSL-3 containment facilities; 5) a highly trained management team and support staff dedicated to the facility who foster collaborations with other institutions. The IVIS Spectrum CT system will be coregistered for use with existing micro PET/CT imaging capabilities in the CVR/RBL Pre-Clinical Imaging Core, overseen by an established management team and operated by trained personnel to maximize access and use for high-priority pathogen research. The combination of increased interest in research on BSL-3/ABSL-3 pathogens with the increasing availability of technologies for expression of bioluminescent/fluorescent reporters from highly pathogenic organisms as well as for monitoring of disease/immune response parameters highlights our need to improve imaging capabilities in containment. Current and anticipated use of the CVR/RBL laboratories includes pathogenesis and challenge studies in mice, rats, rabbits, ferrets and small NHPs, each of which are amenable to imaging in the IVIS Spectrum CT system. Addition of an IVIS Spectrum CT will: 1) satisfy existing research needs; 2) attract additional researchers regionally or even nationally who wish to integrate live animal imaging into their research; and 3) provide an important capability to the RBL emergency response network. Neither bioluminescence/fluorescence in vivo imaging nor micro CT is available within BSL-3/ABSL-3 containment in this region. Moreover, nationally there are only a few such instruments housed in facilities with BSL-3/ABSL-3 containment and Select Agent security. The diversity of pathogens and animal models available in the University of Pittsburgh RBL and the plan to integrate this IVIS Spectrum CT with existing micro PET/CT imaging capabilities provides a truly unique resource.
描述(由申请人提供):此共享仪器赠款(PAR-12-017)要求资金在体内成像系统中购买IVIS Spectrum CT,用于对疾病进展,细胞运输和基因表达模式的非侵入性,纵向监测,这些动物通过生物发光和荧光性动物进行两种变性和三含量的动物,并进行了两种变化的动物,并进行了少量的动物量表。重要的是,该仪器将安置在匹兹堡大学区域生物遏制实验室(RBL)内的临床前成像核心内,提供了三个主要好处:1)在27,000平方英尺的设施内进行住房,目的是为实验室套房和核心设施提供运营的生物安全水平(BSL)-3和Animal Biosafety Level(Absl)-3级别的核心设施-3 2)注册以处理许多精选剂病毒和细菌病原体和毒素; 3)从小鼠到非人类灵长类动物(NHP),在生物遏制笼中的各种动物物种的外壳; 4)与疫苗研究中心(CVR)的关联,其资金丰富的教师具有与这些高度致病生物的研究相关的研究兴趣和专业知识,并利用了RBL BSL-3/ABSL-3遏制设施; 5)训练有素的管理团队和支持人员致力于促进与其他机构合作的设施。伊维斯 Spectrum CT系统将与CVR/RBL临床前成像核心中现有的Micro PET/CT成像功能一起使用,并由既定的管理团队监督,并由训练有素的人员运营,以最大程度地访问并使用高优先级病原体研究。对BSL-3/ABSL-3病原体研究的兴趣增加的兴趣与来自高度致病生物的生物发光/荧光报告的技术的可用性的增加,以及监测疾病/免疫反应参数的增强性,我们需要突出我们需要提高容器中的成像功能。 CVR/RBL实验室的当前和预期的使用包括在小鼠,大鼠,兔子,雪貂和小NHP中进行的发病机理和挑战研究,每个NHP都适合IVIS Spectrum CT系统中的成像。 IVIS Spectrum CT的添加将:1)满足现有的研究需求; 2)在区域甚至希望将活动物成像整合到他们的研究中的其他研究人员中吸引更多的研究人员; 3)为RBL应急网络提供了重要的功能。在该区域的BSL-3/ABSL-3遏制中,在体内成像中均未获得生物发光/荧光。此外,在全国范围内,只有少数此类工具包含在具有BSL-3/ABSL-3遏制和精选代理安全性的设施中。匹兹堡RBL大学可用的病原体和动物模型的多样性以及将IVIS Spectrum CT与现有的Micro PET/CT成像功能相结合的计划提供了真正独特的资源。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

KATHERINE D RYMAN的其他基金

A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine
改善黄热病疫苗的嗜内脏疾病小动物模型
  • 批准号:
    8262675
    8262675
  • 财政年份:
    2011
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine
改善黄热病疫苗的嗜内脏疾病小动物模型
  • 批准号:
    8183819
    8183819
  • 财政年份:
    2011
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine
改善黄热病疫苗的嗜内脏疾病小动物模型
  • 批准号:
    8692632
    8692632
  • 财政年份:
    2011
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine
改善黄热病疫苗的嗜内脏疾病小动物模型
  • 批准号:
    8501251
    8501251
  • 财政年份:
    2011
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Elucidating molecular mechanisms of yellow fever virus virulence
阐明黄热病病毒毒力的分子机制
  • 批准号:
    8067087
    8067087
  • 财政年份:
    2010
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Elucidating molecular mechanisms of yellow fever virus virulence
阐明黄热病病毒毒力的分子机制
  • 批准号:
    7896372
    7896372
  • 财政年份:
    2010
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Determining Molecular Mechanisms of Chikungunya Virulence and Attenuation
确定基孔肯雅热毒力和减毒的分子机制
  • 批准号:
    7996732
    7996732
  • 财政年份:
    2009
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Determining Molecular Mechanisms of Chikungunya Virulence and Attenuation
确定基孔肯雅热毒力和减毒的分子机制
  • 批准号:
    7897893
    7897893
  • 财政年份:
    2009
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Rational design & optimization of new live-attenuated vaccines for alphaviral enc
合理设计
  • 批准号:
    7649158
    7649158
  • 财政年份:
    2008
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
LSUHSC COBRE: ROLE OF INNATE IMMUNITY IN YELLOW FEVER VIRUS PATHOGENESIS
LSUHSC COBRE:先天免疫在黄热病病毒发病机制中的作用
  • 批准号:
    7720565
    7720565
  • 财政年份:
    2008
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:

相似国自然基金

上转换发光纳米材料在不同体型实验动物体内的分布、代谢及生物安全性研究
  • 批准号:
    82160353
  • 批准年份:
    2021
  • 资助金额:
    34 万元
  • 项目类别:
    地区科学基金项目
基于腔肠素类似物的体内生物发光可视化分析研究
  • 批准号:
    81874308
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
基于萤火虫生物发光的体内可视化分析研究
  • 批准号:
    81673393
  • 批准年份:
    2016
  • 资助金额:
    52.0 万元
  • 项目类别:
    面上项目
重组ScFv识别多兽药残留的量子点生物发光共振能量转移技术研究
  • 批准号:
    31672605
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
光学分子影像技术在活体小动物示踪细胞周期的实验研究
  • 批准号:
    31271068
  • 批准年份:
    2012
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目

相似海外基金

Project 2 - Molecular Imaging of ectopic calcification
项目 2 - 异位钙化的分子成像
  • 批准号:
    10628929
    10628929
  • 财政年份:
    2023
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Optical platform for functional longitudinal imaging of metabolite uptake in vivo
用于体内代谢物摄取功能纵向成像的光学平台
  • 批准号:
    10585764
    10585764
  • 财政年份:
    2023
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Synergistically Target Mitochondria for Heart Failure Treatment
协同靶向线粒体治疗心力衰竭
  • 批准号:
    10584938
    10584938
  • 财政年份:
    2023
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
A novel cell-based platform to study human circadian disorders
研究人类昼夜节律紊乱的新型细胞平台
  • 批准号:
    10736091
    10736091
  • 财政年份:
    2023
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别:
Models of EBV Cancer
EBV癌症模型
  • 批准号:
    10627695
    10627695
  • 财政年份:
    2023
  • 资助金额:
    $ 59.93万
    $ 59.93万
  • 项目类别: